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ess: satu.lahelma@orioSummary This randomised, double-blind, double-dummy, cumulative dose, multi-
centre crossover study aimed to demonstrate non-inferiority in safety of formoterol
delivered via Easyhalers versus Aerolizers. The secondary objective was to compare
the efficacy of the devices.
Thirty-three adult asthmatic subjects entered the study and 32 completed it. The
study comprised screening and two study days, with each subject inhaling 96 mg (12,
12, 24 and 48 mg) cumulative dose of formoterol via the study inhalers. Serum
potassium (S-K+), vital signs and spirometry were performed at baseline, 1 h after
each dose and additionally 4 h after the last dose.
The primary safety variable was S-K+. Secondary safety variables were heart rate,
corrected QT interval, blood pressure, serum glucose and adverse events.
Spirometry was assessed to evaluate efficacy.
The results showed non-inferiority in safety of formoterol inhaled via Easyhalers
compared to Aerolizers. The adjusted treatment difference in the S-K+ values after 96mg
cumulative dose of formoterol was 0.14mmol/L being clearly above the pre-determined
lower limit of the non-inferiority criterion of 0.2mmol/L. There were dose-related
changes in secondary efficacy variables after both treatments. The changes were
comparable in most of the parameters but heart rate was statistically significantly higher
and decrease in diastolic blood pressure greater after formoterol via Aerolizers than that
via Easyhalers. The occurrence of adverse events was dose-related, the most common
events being tremor, hypokalaemia, headache and palpitation. The spirometry results
showed no statistically significant difference in efficacy between the treatments.
In conclusion, formoterol delivered via Easyhalers was as safe as via Aerolizers.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
428 6452; fax: +358 10 428 6445.
npharma.com (S. La¨helma¨).
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Table 1 Demographic and baseline characteris-
tics.
Variable All subjects
randomised
(n ¼ 33)
Demography
Male (N, %) 10 (30)
Age (years) (median, range) 44.0 (18.0–70.0)
Height (cm) (median, range) 169.0 (145.0–190.0)
Weight (kg) (median, range) 72.0 (53.0–99.0)
Vital signs
Heart rate (beats/min)
(mean, SD)
64.8 (7.9)
Blood pressure (mmHg)
(mean, SD) systolic
129.8 (13.7)
Diastolic 79.4 (6.9)
Asthma history
Asthma diagnosed (years)
(mean, SD)
4.3 (4.6)
o 2 years before study entry
(N, %)
11 (33)
X 2 years before study entry
(N, %)
22 (67)
Spirometry
FEV1 (L) (mean, SD) 3.12 (0.94)
FEV1 (% of predicted)(mean,
SD)
88.7 (11.4)
FVC (L) (mean, SD) 4.11 (1.23)
MEF50 (L/s) (mean, SD) 3.03 (1.20)
MEF25 (L/s) (mean, SD) 1.14 (0.64)
Number of subjects with
atopic history (N, %)
19 (58)
SD ¼ standard deviation.
J. Randell et al.1486Introduction
Long-acting b2-agonists are the recommended add-
on medication in patients already using inhaled
steroids but having a poor control of their asthma
symptoms.1,2 Formoterol is a potent long-acting,
b2-agonist with the combined beneficial effects of
rapid onset and long duration of action.3,4 The
onset of action after formoterol is the same as for
salbutamol and more rapid than for salmeterol.5
Maximum bronchodilation after formoterol usually
occurs within 2 h of inhalation.3
Formoterol is generally well tolerated and safe,
with the main adverse effects being dose-related
skeletal muscle tremor, palpitation, headache and
muscle cramps.6 Clinically significant cardiac or
metabolic effects are rare. In healthy volunteers,
repeated inhalation of formoterol 24 mg, salbuta-
mol 400 mg or fenoterol 400 mg caused similar
increases in plasma glucose levels, whereas for-
moterol and fenoterol had greater hypokalaemic
effect than salbutamol.7
It is known that delivery devices have different
deposition characteristics.8 With optimal inhalation
technique, pressurised metered dose inhalers (pMDIs)
deliver only about 10–15% of the metered dose to the
lungs, whereas dry powder inhalers (DPIs) such as the
Turbuhalers and Aerolizers deliver 20–35% of the
metered dose to the lungs.8,9 Furthermore, many
patients have difficulty in co-ordinating inhalation
and pMDI actuation. Poor inhaler technique is one of
the key contributing factors to poor symptom control
in patients with asthma.10,11 The problem of co-
ordinating dose release with inspiration is overcome
by DPIs because they use inspiration flow, even at low
rates, to carry the dose into the lungs.12 However,
early DPIs required loading of individual doses, which
is not convenient, particularly for patients with poor
manual dexterity.
Orion Pharma has developed a multidose dry
powder inhaler (MDPI), known as the Easyhalers.
The device is similar in appearance to an pMDI and
does not require co-ordination of actuation and
inspiration.11 Pulmonary deposition studies with
radiolabelled salbutamol,13,14 and budesonide15
indicate that lung deposition of drugs inhaled from
the Easyhalers is 19–29% being comparable to that
of the Turbuhalers. The Easyhalers provides
effective delivery even when inspiratory flow is as
low as 30 L/min.16 Now also formoterol is available
in the Easyhalers device.
In the study reported here, the safety and
efficacy of formoterol when delivered via an
Easyhalers were evaluated and compared with
another dry powder formulation of formoterol:
Foradils Aerolizers.Methods
Subjects
Thirty-six asthmatic subjects were screened for this
study at four centres in Finland (Table 1). Suitable
subjects were non-smokers, aged between 18 and
70 years and had a diagnosis of bronchial asthma.
The clinical diagnosis was supported by one or more
of the following: 412% increase in forced expira-
tory volume in 1 s (FEV1) or 415% increase in peak
expiratory flow (PEF) after short-acting b2-agonist
inhalation; 415% decrease in FEV1 after an
exercise tolerance test; 420% diurnal variability
in PEF on at least 4 days in 1 week. FEV1 had to be
at least 40% of predicted normal within 4 weeks
preceding the study or at the screening visit to
exclude asthmatics with severe and/or uncon-
trolled asthma. The subjects had to have used an
inhaled corticosteroid (200–1000 mg beclometa-
sone or budesonide; or 100–500 mg fluticasone or
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nedocromil sodium (4–8mg) with constant daily
dose for at least 1 month preceding the study.
Subjects were excluded from the study if they
met one or more of the following criteria:
FEV1o40% of the predicted normal value at the
screening visit, hospitalisation due to an exacerba-
tion of asthma, upper and/or lower respiratory
tract infection during the 4 weeks preceding the
screening visit, intake of oral steroids, inhaled long-
acting b2-agonists or leukotriene antagonists within
6 weeks before the screening visit. The presence of
chronic bronchitis or any other severe chronic
respiratory disease other than asthma also excluded
subjects from the study. Subjects were excluded if
any of the following were identified at screening:
manifest heart condition (New York Heart Associa-
tion class I–IV), clinically relevant abnormal ECG
(e.g. QTc40.45 s, extrasystole); resting systolic
blood pressure 4160mmHg, diastolic blood pres-
sure 490mmHg, or heart rate 485beats/min;
serum potassium (S-K+) value o3.5mmol/L; or
concomitant use of b-blockers or drugs to treat
hypertension, or other cardiac drugs.
Concurrent severe hepatic disease or renal
insufficiency, inadequately controlled hyperthyr-
oidism, diabetes, hypersensitivity to any compo-
nents of the formulations, suspected alcohol or
drug abuse, or anticipated non-compliance were
also reasons for excluding subjects from the study.
Women were excluded if they were pregnant or
breast-feeding or, if fertile, did not use reliable
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This was a randomised, double-blind, cumulative
dose, crossover, multicentre study. Subjects were
screened (visit 1) for eligibility, and suitable
subjects were trained in the correct inhalation
technique with each of the dosing devices. After
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of two identical study days (Fig. 1).
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Novartis AG, Switzerland) under the supervision of
study personnel. The study days were separated by
a washout period of between 3 and 7 days. Subjects
were followed-up by telephone between 3 and 7
days after the second study day and were seen
again in the clinic if necessary.
Prior to each visit and during the study days,
subjects were required to avoid the following
medications: inhaled short-acting b2-agonists for
at least 6 h; inhaled anticholinergics for at least 8 h;
oral b2-agonists for at least 24 h; antihistamines,
aspirin and other non-steroidal anti-inflammatory
drugs for at least 48 h; cough medicines containing
salbutamol and ephedrine, and theophylline pre-
parations for at least 72 h. In addition, the subjects
were not allowed to consume tea, coffee or cola
drinks for 8 h and alcohol for 12 h before or during
any visit.
The study was conducted according to the
protocol, Good Clinical Practice (ICH/135/95) and
all applicable local regulatory requirements. The
study protocol and other relevant documents were
reviewed and approved by the Ethics Committees
of the Hospital District of North Savo at the Kuopio
University Hospital and all subjects provided
written informed consent before undergoing any
study-specific procedures.Outcome variables
The primary outcome variable was S-K+. The
secondary safety variables were those intended to
assess the extra-pulmonary effects of formoterol
and included heart rate, corrected QT interval
(QTc, Bazett’s correction), blood pressure, serum
glucose, tremor in hands, and adverse events.
Tremor was evaluated visually with scale 1 ¼ no
tremor or writing impairment, 2 ¼ mild tremor,
writing and drawing slightly impaired, 3 ¼ severe
tremor, writing and drawing severely impaired,
interferes with many activities. The efficacy vari-
ables, all of which were secondary, included FEV1,
forced vital capacity (FVC) and maximal expiratory
flow when 25% and 50% of the FVC remains to be
exhaled (MEF25 and MEF50, respectively).
All of the outcome variables were measured at
baseline, 1 h after each cumulative dose and 4 h
after the last dose of study medication on each
study day.Statistical analysis
The primary analysis of S-K+ was performed using an
analysis of covariance (ANCOVA) with the baselinemeasurement as a covariate. Inference in the
primary analysis was based on a one-sided 97.5%
confidence interval (CI) against a pre-specified non-
inferiority criterion. A similar model was also used
in the analysis of heart rate but a non-inferiority
criterion was not specified for this variable. The
95% CIs for treatment differences are reported for
two-sided tests.
S-K+, heart rate, QTc interval, blood pressure and
lung function variables were analysed using random
coefficients ANCOVA with baseline measurement as
a covariate. In these analyses, values measured at
each timepoint were used to calculate the overall
differences. In addition, for S-K+ and heart rate,
the mean of the last two measurement time points
were analysed. Tremor was analysed using a
Cochran–Mantel–Haenszel test. Abnormal values
for S-K+ was analysed using logistic regression.17
The area under the curve (AUC) of FEV1 was
analysed using ANCOVA.
All the other analyses were performed on the
analysis set that included all subjects who were
eligible for the study, took all doses of study
medication, had at least one useable measurement
from the last two blood samples available and no
significant protocol violations (N ¼ 28), except
analysis of adverse events included all randomised
subjects (N ¼ 33).
The estimated sample size was for at least 32
subjects recruited to ensure a minimum of 22
evaluable subjects. This was based on previous
experience that the within-subject variance in S-K+
was approximately 0.03mmol/L. The lower limit of
the equivalence range was set at 0.2mmol/L and
a paired t-test with a 2.5% one-sided significance
level had 95% power to determine equivalence.Results
Subjects
Thirty-six subjects were screened for the study and
33 of these subjects were eligible for enrolment.
Thirty-two of the subjects enrolled completed both
study days. One subject completed the first study
day (Easyhalers) but on the second study day, the
highest baseline FEV1 was not 715% of the highest
pre-dose FEV1 of the first study day. Therefore, the
subject was withdrawn from the study before
dosing on the second study day.
All 33 subjects enrolled were Caucasian and more
than two-thirds of the subjects were female (Table
1). Twenty-five subjects had mild (FEV1 over 80% of
predicted) and eight subjects had moderate (FEV1
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asthma. All subjects were taking inhaled corticos-
teroids (beclometasone, budesonide or fluticasone)
for their asthma. Thirty-one subjects (94%) used
short acting b2-agonists on demand. Twenty-nine
subjects had concurrent diseases at screening, the
most common being allergic rhinitis (15 subjects)
and 27 subjects took concomitant medications
for conditions other than asthma. The most
common concomitant medication was ibuprofen (8
subjects).Cumulative dose (µg)
S-
K+
 
(m
ol/
l)
0.0
0.2
3.0
3.2
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Figure 2 S-K+ (mmol/L) after cumulative doses of
formoterol (N ¼ 28). Values are mean7standard error
of the mean. *Statistically significant difference
(Po0:05) between the treatments in the means of the
last two values.Primary outcome variable
The effect of 96 mg cumulative dose of formoterol
on S-K+ when administered using the Easyhalers
was not inferior to that after administration via the
Aerolizers (Table 2). The adjusted treatment
difference for the mean of the last two S-K+ values
was 0.14mmol/L (95% CI from 0.02 to 0.26) being
clearly above the pre-determined lower limit of the
non-inferiority criterion of 0.2mmol/L.
Baseline S-K+ concentrations on both study days
were within the normal range (3.7–5.3mmol/L)
except for three subjects who had S-K+ value of
3.6mmol/L on the first study day (Aerolizers) and
one of these subjects who continued to have low S-
K+ (3.4mmol/L) on the second study day (Easy-
halers). However, overall, mean S-K+ values
decreased with increasing dose of formoterol with
both dosing devices but showed signs of recovery
immediately after the last dose (Fig. 2). In general,
cumulative dose of formoterol inhaled from the
Aerolizers decreased S-K+ values more than for-
moterol inhaled from the Easyhalers. The lowest
individual S-K+ value recorded was 2.8mmol/L.
The greatest differences between the dosing
devices in abnormal S-K+ values occurred after the
48 and 96 mg cumulative doses of formoterol. The
number of subjects with abnormal S-K+ values 1 h
after 48 mg formoterol was 4 (12%) for the Easy-
halers and 10 (31%) for the Aerolizers. One hour
after 96 mg formoterol, the number of subjects with
abnormal S-K+ values was 18 (55%) and 26 (81%) forTable 2 Mean (SD) S-K+ (mmol/L) at baseline and the mea
dose of formoterol; difference and 95% CI.
Treatment S-K+ (mmol/L) (N ¼ 28)
Baseline After 96 mg
Easyhalers 4.23 (0.32) 3.71 (0.31)
Aerolizers 4.18 (0.31) 3.56 (0.31)
SD ¼ standard deviation.the Easyhalers and Aerolizers, respectively. The
number of subjects with at least one abnormal S-K+
value at any measurement time point was 22 after
the Easyhalers and 26 after the Aerolizers
(Po0:001).
Other extrapulmonary effects of formoterol
At the lower doses (12, 24 and 48 mg formoterol),
mean heart rate values remained quite stable with
both treatments compared with baseline. However,
after the cumulative 96 mg dose, the mean (SD) of
the last two measurements following dosing with
the Easyhalers was 71.1 (8.7) beats/min compared
with 75.4 (10.5) beats/min using the Aerolizers.
The adjusted difference was 3.8 and it was
statistically significant (95% CI from 6.3 to
1.4). The individual maximum heart rate value
was 110 beats/min, which was recorded after the
cumulative 96 mg dose of formoterol with the
Aerolizers.
There was an initial slight decrease in QTc after
both treatments following 12 mg of formoterol.
Thereafter, a dose-related increase in QTc occurredn of the last two measurements after 96 mg cumulative
Adjusted difference (Easyhalers—Aerolizers)
After 96 mg 95% CI
0.14 0.02 to 0.26
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Table 3 Spirometry at baseline and 1 h after
cumulative 96 mg dose of formoterol.
Spirometry
variable (mean, SD)
Easyhalers
(N ¼ 28)
Aerolizers
(N ¼ 28)
FEV1 (L)
Baseline 2.99 (0.93) 2.95 (0.91)
96 mg formoterol 3.27 (1.04) 3.28 (1.04)
FVC (L)
Baseline 3.90 (1.17) 3.88 (1.17)
96 mg formoterol 4.03 (1.20) 4.01 (1.19)
MEF50 (L/s)
Baseline 3.01 (1.30) 2.93 (1.39)
96 mg formoterol 3.72 (1.45) 3.76 (1.45)
MEF25 (L/s)
Baseline 1.19 (0.65) 1.08 (0.71)
96 mg formoterol 1.56 (1.02) 1.59 (0.91)
SD ¼ standard deviation.
J. Randell et al.1490with both treatments. The highest mean QTc values
were observed 1 h after the cumulative 96 mg dose
of formoterol. After the Easyhalers, the mean (SD)
baseline QTc was 396.9 (21.1)ms and increased by
17.4ms after the cumulative 96 mg dose. After the
Aerolizers, the change in mean QTc from baseline
was 19.9ms. The adjusted difference was 4.4 but
was not statistically significant (95% CI from 9.5 to
0.6). There were no individuals with QTc 4450ms
after 12 and 24 mg formoterol. Two subjects had QTc
values4450ms after both 48 and 96 mg cumulative
doses of formoterol when administered via the
Easyhalers. No subjects had QTc 4450ms after
48 mg doses of formoterol via the Aerolizers but
four subjects had QTc values 4450ms after 96 mg
dose.
There was no change from baseline in systolic
blood pressure after either of the two treatments.
Diastolic blood pressure decreased slightly with
increasing dose of formoterol. The mean values
were 5.0mmHg lower than baseline after cumula-
tive 96 mg formoterol from the Easyhalers and
5.8mmHg lower at the same time point after dosing
from the Aerolizers. The adjusted overall differ-
ence between the groups was 2.0mmHg (95% CI
from 0.3 to 3.7).
Serum glucose increased slightly with increasing
dose of formoterol. After the Easyhalers treat-
ment, mean (SD) glucose was 5.0 (0.6)mmol/L at
baseline and 6.0 (0.8)mmol/L one hour after the
cumulative 96 mg dose. After the Aerolizers, these
values were 5.1 (0.7) and 6.3 (1.0)mmol/L,
respectively. One hour after the cumulative 96 mg
dose, one subject had serum glucose levels
47.8mmol/L after both treatments and a further
two individuals had serum glucose levels above this
value after the Aerolizers treatment only.
The incidence of tremor of the hands increased
with increasing doses but there were no statisti-
cally significant differences in individual tremor
scores between the treatments. No tremor was
reported after the 12 mg dose in either treatment
group. After the cumulative dose of 96 mg formo-
terol only three subjects per treatment did not
report tremor, and severe tremor was reported by
six subjects after both treatments.Spirometry
Spirometry findings are presented in Table 3. No
statistically significant differences between the
two treatments for efficacy following a cumulative
96 mg dose of formoterol were detected. For FEV1
the greatest increase occurred after the first
(12 mg) dose (Fig. 3). The mean (SD) AUC of FEV1for the Easyhalers was 1490.5 (468.7) L over time
and for the Aerolizers 1498.3 (466.4) L over time
(Easyhalers/Aerolizers ratio 0.981, 95% CI from
0.97 to 1.00). Mean (SD) FEV1 1 h after the first dose
of formoterol was 3.12 (0.97) L after dosing via the
Easyhalers and 3.16 (0.95) L after dosing via the
Aerolizers. Similarly, the greatest increase in MEF50
and MEF25 values was seen after the 12 mg dose of
formoterol with both study treatments. The in-
crease in mean MEF50 after the 12 mg dose was
0.5 L/s with the Easyhalers and 0.68 L/s with the
Aerolizers.Adverse events
Every subject experienced one or more adverse
events during the study. Thirty-two subjects ex-
perienced a total of 158 adverse drug reactions
(ADRs), i.e. adverse events that were possibly or
probably related to study treatment: 70 ADRs on
the Easyhalers (90% of the total number of adverse
events after this treatment) and 88 (91%) on the
Aerolizers.
Most ADRs occurred after the 96 mg cumulative
dose of formoterol (Table 4). The most common
ADRs were those that were expected, i.e. tremor,
hypokalaemia, headache and palpitation. There
was a clear dose-related effect of treatment on the
incidence and severity of ADRs. One episode of
tremor was severe (Aerolizers), and there was also
one severe toothache (Aerolizers). All other ADRs
were mild or moderate. There were no serious
adverse events and no subjects were withdrawn
from the study due to adverse events.
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In this randomised, double-blind, crossover study,
the safety and efficacy of formoterol was evaluated
after 96 mg cumulative dose. Formoterol was
administered via two different dry powder inhaler
devices: the Easyhalers and Aerolizers. For the
comparison of the devices with the same drug
substances a cumulative dose study instead of long-
term treatment was considered sufficient. In order
to achieve a meaningful outcome after just one
dosing day, the cumulative dose of formoterol was
intentionally two-fold greater than the recom-
mended therapeutic dose in regular use. The study
population consisted of adult asthmatic patients
who were all using inhaled corticosteroids.
The results of the study show non-inferiority
in safety of formoterol inhaled via EasyhalersTable 4 Number of subjects experiencing most common
lowest dose at which reaction was identified).
Adverse drug reaction Cumulative dose of formotero
Easyhalers (N ¼ 33)
12 24 48
Tremor 6 12
Hypokalaemia 2
Headache
Palpitation
Hyperglycaemia
Tachycardia 1
Agitation
Cumulative dose (µg)
Baseline 12 24 48 96 96/4h 
FE
V 1
 
(L)
0.0
0.2
2.6
2.8
3.0
3.2
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3.6
3.8
Easyhaler®
Aerolizer®
Figure 3 FEV1 (L) after inhalation of cumulative doses of
formoterol (N ¼ 28). Spirometry was performed 1 h after
the administration of each dose and additionally 4 h after
the last dose. Values are mean7standard error of the
mean.compared to Aerolizers when S-K+ values after
96 mg cumulative dose are compared. S-K+ is known
to decrease after administration of b2-agonists such
as formoterol.18,19 The proposed mechanism by
which this occurs is stimulation of b2-adrenoceptors
leading to a shift of extracellular potassium to the
intracellular space by activation of the sodium–po-
tassium pump via adenyl cyclase in the cell
membrane.20 Total body potassium remains con-
stant.
In studies of healthy volunteers18 and in patients
with asthma,21,22 potassium levels decreased sig-
nificantly only with higher doses of formoterol
(X48 mg). Therefore, the primary safety variable
chosen for comparison between two dosage devices
of formoterol was the difference in mean S-K+
values measured 1 and 4 h after the last (96 mg)
cumulative dose of drug. The lower limit of the
equivalence range was pre-set at –0.2mmol/L. The
findings of the present study support those of other
studies in that S-K+ values were affected most by
the two highest cumulative doses of formoterol (48
and 96 mg). However, after the 96 mg cumulative
dose, S-K+ was statistically significantly lower after
dosing from the Aerolizers compared with the
Easyhalers.
As with other b2-agonists, formoterol is known to
cause a dose-related prolongation of the QT
interval.6 This is mediated in part by cardiac b2-
adrenoceptor stimulation in addition to a reduction
in serum or plasma potassium. There are different
opinions on the significance in man of the slight
hypokalaemia that can occur after administration
of very high doses of inhaled b2-agonists. Further-
more, it is not certain whether the rapid changes in
the extracellular concentrations of potassium that
may follow high doses of these agents are asso-
ciated with the development of cardiac arrhyth-
mias. In the study reported here, the incidence of
high QTc values (4450ms) was uncommon andadverse drug reactions after each study treatment (the
l (mg)
Aerolizers (N ¼ 32)
96 12 24 48 96
18 10 11 14
13 1 1 20
2 1 5
3 1 4
2 3
1 2
1 1 1 1
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doses. Lowered S-K+ levels and prolonged QTc
intervals may predispose to cardiac arrhythmias.
In this study, one report of atrial arrhythmia was
reported after the cumulative 96 mg dose via the
Easyhalers but was not clinically significant.
Other expected adverse effects of b2-agonists
include increased heart rate and decreased blood
pressure.6,18,21 Again the findings of this study
support the expected effects of formoterol. How-
ever, there was a continued pattern of greater
systemic effects after dosing via the Aerolizers
compared with the Easyhalers.
The spirometry assessment results showed no
statistically significant differences in efficacy of
cumulatively inhaled 96 mg formoterol administered
from the Easyhalers compared with the Aeroli-
zers. The greatest increase in FEV1 occurred for
both dosing devices after the first 12 mg dose of
formoterol, which is the dose most commonly
studied, and causes clinically clear, although not
always maximal, effects.22–25 Most subjects in this
study had maximum FEV1 values only after the
96 mg cumulative dose of formoterol.
Clinical studies have repeatedly shown that
dosing using the Easyhalers is therapeutically
equivalent to other inhalers in terms of efficacy
and safety when this dosage device is used in dosing
of budesonide,26–28 salbutamol29–31 and beclome-
tasone dipropionate.29,32–34 Furthermore, most
patients find the Easyhalers easier to use than
pMDI or other DPIs.35,36 There were no assessments
on ease of use in the study reported here. However,
it is reasonable to extrapolate the findings of the
other studies to suggest that the Easyhalers is
convenient to use also in dosing of formoterol.
Overall, the results of this study show that the
extrapulmonary effects of formoterol are dose-
related with no safety concerns at the 12 and 24 mg
doses, and predictable adverse drug reactions at 48
and 96 mg.
In conclusion, formoterol administered via the
Easyhalers is non-inferior to the Aerolizers in
terms of safety after cumulative 96 mg dosing. The
two dosing devices are not different in terms of
efficacy in subjects with asthma.Acknowledgements
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